These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

547 related articles for article (PubMed ID: 29900892)

  • 41. Parallel assessment of 24 monthly doses of rifampin, ofloxacin, and minocycline versus two years of World Health Organization multi-drug therapy for multi-bacillary leprosy.
    Villahermosa LG; Fajardo TT; Abalos RM; Cellona RV; Balagon MV; Dela Cruz EC; Tan EV; Walsh GP; Walsh DS
    Am J Trop Med Hyg; 2004 Feb; 70(2):197-200. PubMed ID: 14993633
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Daily multidrug therapy for leprosy; results of a fourteen-year experience.
    de Carsalade GY; Wallach D; Spindler E; Pennec J; Cottenot F; Flageul B
    Int J Lepr Other Mycobact Dis; 1997 Mar; 65(1):37-44. PubMed ID: 9207752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Leprosy treatment during pregnancy and breastfeeding: A case report and brief review of literature.
    Ozturk Z; Tatliparmak A
    Dermatol Ther; 2017 Jan; 30(1):. PubMed ID: 27549245
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Does clofazimine have a prophylactic role against neuritis?
    Arunthathi S; Satheesh KK
    Lepr Rev; 1997 Sep; 68(3):233-41. PubMed ID: 9364824
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy and safety of multidrug therapy in paucibacillary leprosy in Singapore.
    Lim JT; Tan T
    Lepr Rev; 1993 Jun; 64(2):136-42. PubMed ID: 8341116
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of two multidrug regimens in multibacillary leprosy.
    Jadhav VH; Patki AH; Mehta JM
    Indian J Lepr; 1992; 64(4):501-4. PubMed ID: 1308526
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction of constituents of MDT regimen for leprosy with Mycobacterium leprae HSP18: impact on its structure and function.
    Chakraborty A; Ghosh R; Biswas A
    FEBS J; 2022 Feb; 289(3):832-853. PubMed ID: 34555271
    [TBL] [Abstract][Full Text] [Related]  

  • 48. [Guidelines for the treatment of Hansen's disease in Japan (third edition)].
    Goto M; Nogam R; Okano Y; Gidoh M; Yotsu R; Ishida Y; Kitajima S; Kai M; Ishii N; Ozaki M; Hatano K; ;
    Nihon Hansenbyo Gakkai Zasshi; 2013 Dec; 82(3):143-84. PubMed ID: 24579462
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Once monthly rifampicin (1200 mg) plus daily dapsone (100 mg) and clofazimine (100 mg) in the initial treatment of lepromatous leprosy.
    Chandorkar AG; Burte NP; Gade RK; Bulakh PM
    Indian J Lepr; 1984; 56(1):63-70. PubMed ID: 6384381
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Two microbiological relapses in a patient with lepromatous leprosy.
    Chakma JK; Girdhar A; Natrajan M; Kumar A; Girdhar BK
    Lepr Rev; 2008 Sep; 79(3):331-4. PubMed ID: 19009984
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effect of three-year multidrug therapy in multibacillary leprosy patients.
    Li W; Ye G; Yang Z; Tao M; Luo J; Wang C; Ji F
    Proc Chin Acad Med Sci Peking Union Med Coll; 1990; 5(1):37-40. PubMed ID: 2371263
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparative study of short term results in two multidrug regimens in multibacillary leprosy.
    Singh RP; Tiwari VD; Chattopadhyay SP
    Indian J Lepr; 1993; 65(2):173-80. PubMed ID: 8345231
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular detection of multidrug-resistant Mycobacterium leprae from Indian leprosy patients.
    Lavania M; Singh I; Turankar RP; Ahuja M; Pathak V; Sengupta U; Das L; Kumar A; Darlong J; Nathan R; Maseey A
    J Glob Antimicrob Resist; 2018 Mar; 12():214-219. PubMed ID: 29097343
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunochemotherapy with interferon-gamma and multidrug therapy for multibacillary leprosy.
    Barral-Netto M; Santos S; Santos I; von Sohsten R; Bittencourt AL; Carvalho EM; Barral A; Waters M
    Acta Trop; 1999 Mar; 72(2):185-201. PubMed ID: 10206118
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Severe type 1 upgrading leprosy reaction in a renal transplant recipient: a paradoxical manifestation associated with deficiency of antigen-specific regulatory T-cells?
    Vieira AP; Trindade MAB; de Paula FJ; Sakai-Valente NY; Duarte AJDS; Lemos FBC; Benard G
    BMC Infect Dis; 2017 Apr; 17(1):305. PubMed ID: 28438129
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Long-term efficacy of 2 year WHO multiple drug therapy (MDT) in multibacillary (MB) leprosy patients.
    Cellona RV; Balagon MF; dela Cruz EC; Burgos JA; Abalos RM; Walsh GP; Topolski R; Gelber RH; Walsh DS
    Int J Lepr Other Mycobact Dis; 2003 Dec; 71(4):308-19. PubMed ID: 14763888
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Ofloxacin-containing combined drug regimens in the treatment of lepromatous leprosy.
    Rao PS; Ramachandran A; Sekar B; Ravi S; Subramanian M
    Lepr Rev; 1994 Sep; 65(3):181-9. PubMed ID: 8942149
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Relapses in multibacillary leprosy patients: a retrospective cohort of 11 years in Colombia.
    Guerrero-Guerrero MI; Muvdi-Arenas S; León-Franco CI
    Lepr Rev; 2012 Sep; 83(3):247-60. PubMed ID: 23356026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Why multidrug therapy for multibacillary leprosy can be shortened to 12 months.
    Ji B
    Lepr Rev; 1998 Jun; 69(2):106-9. PubMed ID: 9715593
    [No Abstract]   [Full Text] [Related]  

  • 60. Clinical oxidative stress during leprosy multidrug therapy: impact of dapsone oxidation.
    Schalcher TR; Borges RS; Coleman MD; Batista Júnior J; Salgado CG; Vieira JL; Romão PR; Oliveira FR; Monteiro MC
    PLoS One; 2014; 9(1):e85712. PubMed ID: 24465659
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.